eligibility_summary
Eligibility: Consent, able to take PO meds, age >80 or 61–80 and R-CHOP–ineligible, contraception if applicable, untreated CD20+ DLBCL (WHO subtypes ok), stage I bulky ≥7.5 cm–IV, ECOG 0–2 or 3 from lymphoma, adequate counts/liver/renal. Severe cardiac/pulmonary/psychiatric/neuro disease or GI malabsorption, active infection (HIV, HBV/HCV PCR+), PML, CNS lymphoma/Richter, recent stroke/major surgery, pregnancy/breastfeeding, warfarin, strong CYP3A drugs, PPIs, prior BTKi, high anthracycline, prior tx (except limited prephase).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 randomized trial in older adults with untreated CD20+ DLBCL tests acalabrutinib plus R-miniCHOP vs R-miniCHOP to improve progression-free survival. Interventions and mechanisms (type): Acalabrutinib - oral covalent BTK inhibitor blocking B-cell receptor (BCR) signaling, reducing B-cell proliferation/survival. Rituximab - anti-CD20 monoclonal antibody depleting B cells via ADCC, CDC, and apoptosis. Cyclophosphamide - alkylating agent causing DNA crosslinks. Doxorubicin - anthracycline/topoisomerase II inhibitor and DNA intercalator generating ROS. Vincristine - vinca alkaloid disrupting microtubules/mitosis. Prednisolone - glucocorticoid inducing lymphocyte apoptosis. Targets/pathways: malignant CD20+ B cells, BTK/BCR signaling, DNA integrity/replication, mitotic spindle, glucocorticoid receptor-mediated apoptosis.